TO THE EDITOR
Bone disease in multiple myeloma (MM) is characterized by increased bone resorption and impaired osteoblast activity, resulting in lytic bone lesions. 1 Therefore, the biochemical markers of osteoblastic activity seem not elevated in most cases of MM. Recently, bortezomib, a proteasome inhibitor, has been shown to have an antimyeloma activity by blocking nuclear factor-kB (NF-kB)-mediated IL-6 production from bone marrow (BM) microenvironment, and inducing apoptosis of myeloma cells. 2 It acts in the BM microenvironment to inhibit the binding of myeloma cells to BM stromal cells, the transcription and secretion of IL-6 triggered by myeloma cells to BM stromal cell adhesion, and BM angiogenesis. Phase II trial of bortezomib in patients with refractory MM demonstrated the overall response rate of 35%, with 10% of patients being in complete response (CR). 3 However, the effect of bortezomib on bone lesions remains unknown. We here report a patient with MM who showed the high serum total alkaline phosphatase (ALP) as well as bone-specific alkaline phosphatase (BAP) levels after bortezomib-combined therapy, which suggests that bortezomib induced osteoblastic differentiation.
A 61-year-old male was referred to our hospital because of the compression fractures in thoraco-lumbar vertebrae in July 2002. , 11, and 12) were also administrated. On day 6, serum LDH level significantly elevated to 2280 IU/l probably due to tumor lysis, then gradually decreased and normalized 3 weeks later. Serum IgG level was decreased to 673 mg/dl on day 12, and BM aspiration on day 30 showed hypocellularity with 2% myeloma cells, while serum ALP level had been progressively elevated since 2 weeks after the beginning of bortezomib, and reached 2465 IU/l on day 33. At that time, the majority of serum ALP consisted of ALP-3 by electrophoresis. Enzyme immunoassay confirmed that serum BAP was significantly elevated to 376.0 U/l (normal range 13.0-33.9 U/l). Then, serum ALP level was gradually decreased, but had been maintained 41000 IU/l for more than 1 month without disease progression (Figure 1) . It is known that more than 95% of the serum ALP activity is derived from hepatocytes and osteoblasts. Therefore, in patients with normal liver function, serum ALP seems available as the index of bone formation. Indeed, serum ALP as well as BAP levels were elevated in our case after bortezomib-combined therapy. Bisphosphonate has been reported as the potent inhibitor of osteoclastic activity and to reduce the skeletal complications in MM. 4 But our patient did not show the definite elevation of serum ALP levels after prior incadronate-containing salvage therapy, and the inability of bisphosphonate to repair lytic bone lesions indicates that the functional defect of osteoblasts is also important in the lytic process. 5 In this case, he showed the remarkable elevation of serum ALP as well as BAP levels after receiving bortezomib in combination with incadronate and dexamethasone. Our case suggested that bortezomib might have an effect on the osteoblastic activity in addition to antimyeloma activity. The possible mechanism is the rapid disappearance of myeloma cells induced by bortezomib. Myeloma cells secrete at least two molecules that modulate the bone microenvironment in a manner favorable to tumor growth. Receptor activator of NF-kB ligand (RANKL) acts to stimulate osteoclast formation and activity, leading to bone erosion, whereas dickkopf1 (DKK1) appears to inhibit osteoblasts by the Wnt signal pathway, thus preventing repair of the lesions. 5 Thus, removal of myeloma cells decreased the inhibition of DKK1 on canonical Wnt signal pathway, resulting in osteoblast differentiation. 6 Activation of canonical Wnt pathway induces ALP activity. 7 Another mechanism is that bortezomib directly inhibited the secretion of DKK1 from osteoblasts, which results in the activation of Wnt signal pathway and osteoblast differentiation. Recently, Oyajobi et al demonstrated that bortezomib inhibited DKK1 expression in cell lines of mesenchymal origin, and stimulated the new bone formation in neonatal mouse calvariae. 2, 3 where cells expressed established targets of Imatinib like BCR-ABL, c-Kit, PDGF-receptor, the detection of proapoptotic effects of Imatinib in cells of lymphatic origin lacking these targets is intriguing and opens up new possible fields of application for Imatinib. While testing the effect of Imatinib on BCR-ABL, c-KIT and PDGFR-negative cells gained from CLL patients in vitro we found that in certain cases Imatinib alone, applicated in clinically achievable concentrations of 0-20 mM, was able to induce apoptosis in these cells. However, the tested cells could clearly be segregated into 'responders' to Imatinib displaying regular dose-response curves and 'nonresponders', which were not affected by treatment with Imatinib. Similar results could be produced when testing cell lines of lymphatic origin such as DOHH-2, WSU-NHL, Karpas299, Raji, HUT78 and Jurkat, which are all deficient of
